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Construction of an Escherichia coli expression vector for the non-structural (NS)-1 
protein of avian influenza virus H5N1
(Pembangunan vektor pengekspresan Escherichia coli untuk protein non-struktural (NS)-1 virus influenza 
unggas H5N1)
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ABSTRACT
In the search for universal vaccine candidates for the prevention of avian influenza, the non-structural (NS)-1 protein of 
avian influenza virus (AIV) H5N1 has shown promising potential for its ability to effectively stimulate the host immunity. 
This study was aimed to produce a bacterial expression plasmid using pRSET B vector to harbour the NS1 gene of AIV 
H5N1 (A/Chicken/Malaysia/5858/2004 (H5N1)) for protein expression in Escherichia coli (E. coli). The NS1 gene (687 
bp) was initially amplified by polymerase chain reaction (PCR) and then cloned into a pGEM-T Easy TA vector. The NS1 
gene was released from pGEM-T-NS1 using EcoRI and XhoI restriction enzymes (RE). The pRSET B vector was also 
linearized using the same RE. The digested NS1 gene and linearized pRSET B were ligated using T4 DNA ligase to form 
the expression plasmid, pRSET B-NS1. The NS1 gene sequence in pRSET B-NS1 was confirmed by DNA sequencing. To 
prepare recombinant bacterial cells for protein expression in the future, pRSET B-NS1 was transformed into E. coli strain 
BL21 (DE3) by heat-shock. Colonies bearing the recombinant plasmid were screened using PCR. The DNA sequencing 
analysis revealed that the NS1 gene sequence was 97% homologous to that of AIV H5N1 A/Chicken/Malaysia/5858/2004 
(H5N1). These results indicated that the NS1 gene of influenza A/Chicken/Malaysia/5858/2004 (H5N1) was successfully 
amplified and cloned into a pRSET B vector. Bacterial colonies carrying pRSET B-NS1 can be used for the synthesis of 
NS1-based influenza vaccine in the future and thereby aid in the prevention of avian influenza.
Keywords: NS1; avian influenza; H5N1; vaccine; protein expression
ABSTRAK
Dalam usaha menemui calon vaksin universal untuk pencegahan influenza unggas, protein bukan struktur (NS)-1 virus 
flu burung (AIV) H5N1 telah menunjukkan potensi yang memberangsangkan dalam merangsang imuniti perumah 
secara berkesan. Kajian ini bertujuan untuk menghasilkan plasmid pengekspresan bakteria dengan menggunakan 
vektor pRSET B bagi membawa gen NS1 virus AIV H5N1 (A/Chicken/ Malaysia/5858/2004 (H5N1)) untuk tujuan 
pengekspresan protein dalam Escherichia coli (E. coli). Gen NS1(687 bp) diperbanyak melalui reaksi berantai 
polimerase (PCR) dan kemudian diklonkan ke dalam vektor TA pGEM-T Easy. Seterusnya, gen NS1 dibebaskan dari 
pGEM-T-NS1 dengan enzim restriksi EcoRI dan XhoI. Vektor pRSET B juga dilinearkan dengan enzim restriksi yang 
sama. Gen NS1 dan pRSET B kemudian digabungkan dengan menggunakan enzim T4 DNA ligase untuk membentuk 
plasmid pengekspresan, pRSET B-NS1. Jujukan gen NS1 dalam pRSET B-NS1 disahkan melalui kaedah penjujukan 
DNA. Untuk menyediakan sel bakteria rekombinan bagi pengekspresan protein kelak, pRSET B-NS1 dimasukkan ke 
dalam E. coli strain BL21 (DE3) melalui kaedah kejutan panas. Koloni yang membawa plasmid rekombinan disaring 
dengan menggunakan PCR. Keputusan penjujukan DNA menunjukkan bahawa jujukan gen NS1 adalah 97% homologus 
dengan gen NS1 AIV H5N1 A/Chicken/Malaysia/5858/2004 (H5N1). Hasil ini menunjukkan bahawa gen NS1 influenza 
A/Chicken/Malaysia/5858/2004(H5N1) telah berjaya diamplifikasikan dan diklonkan ke dalam vektor pRSET B. Koloni 
bakteria yang membawa pRSET B-NS1 boleh digunakan untuk mensintesis vaksin influenza berasaskan NS1 pada masa 
akan dating, dengan itu, membantu dalam pencegahan influenza unggas.






Avian influenza virus (AIV) strain H5N1 is a highly 
pathogenic influenza A virus that causes severe respiratory 
illnesses in birds. Close contact with infected poultry 
increases the opportunity of AIV H5N1 to spill over and 
cause infections in human (Alexander et al. 2018). The 
first reported H5N1 infection in human occurred in Hong 
Kong in 1997 (Claas et al. 1998), followed by re-emergence 
in Asia in 2003 and 2006 (Peiris et al. 2004; WHO 2009). 
According to World Health Organization (WHO), AIV 
H5N1 has caused 861 cases with 455 death in 17 countries 
since 2003 (WHO 2020). The ability of AIV H5N1 to breach 
the birds-to-human species barrier is driven by 2 major 
mutational changes: (1) point mutations that alter the 
affinity of the viral hemagglutinin (HA) protein to sialic 
acid receptors on host cells (Crusat et al. 2013), and (2) 
gene reassortment with human-adapted influenza A 
subtypes (Schrauwen et al. 2013). This gives rise to the 
emergence of new AIV strains which possibly cause global 
influenza pandemics with high morbidity and mortality 
(Webster & Govorkova 2014).
Vaccination  is by far one of the most effective 
preventive measures against influenza (Lee & Shah 2012). 
The commercially available influenza vaccines are made 
based on virus surface antigens: hemagglutinin (HA) and 
neuraminidase (NA) of recently circulating strains (Wong 
& Webby 2013). In general, production of influenza 
vaccines involves embryonated chicken eggs and therefore 
requires long production time (Lu et al. 2017). Furthermore, 
the vaccines are only effective against homologous 
influenza subtypes and may potentiate allergic reactions 
against egg proteins in certain individuals (Soema et al. 
2015). Due to the rapid antigenic change among the 
circulating influenza strains, it requires annual reformulation 
of flu vaccines. In addition, since the conventional influenza 
vaccines only target the circulating influenza subtypes, 
they do not protect humans from a novel, potential 
pandemic strain. Therefore, a universal vaccine candidate 
that can induce cross-protection against the majority of 
influenza subtypes is needed (Sautto et al. 2018).  
The influenza non-structural (NS)-1 protein is a 
relatively conserved protein among influenza A subtypes. 
It is a multifunctional protein involved in the viral 
replication and inhibition of host immune responses (Tynell 
et al. 2014). Although the NS1 protein has been shown to 
inhibit the host immunity especially the type-1 interferon 
(IFN) responses when it is produced abundantly on infected 
cells (Kuo et al. 2016; Li  et al. 2010), a number of studies 
demonstrated that influenza viruses carrying mutated NS1 
genes or small quantities of NS1 protein on virus particles 
could induce protective responses against the virus 
infections and hence attenuation of the disease symptoms 
in animal models (Richt & Garcia-Sastre 2009; Steel et al. 
2009). Surprisingly, this protective response were not only 
limited to the homologous influenza strains but also 
effective against heterologous strains, thus indicating a 
broad, cross-neutralizing response induced by the 
recombinant influenza viruses (Steel et al. 2009). Given 
its conserved amino acid sequences among influenza strains 
and ability to induce protective immune responses, this 
suggests the potential of influenza NS1 protein as a 
universal vaccine candidate.
Owing to newer advances in the field of recombinant 
DNA technology, several types of pathogen-free vaccines 
such as recombinant subunit vaccines have been developed 
and proven to be effective in preventing contagious 
infections, for instance, hepatitis B (Michel & Tiollais 
2010) and human papillomavirus (Schiller et al. 2012). The 
use of recombinant DNA technology in vaccine development 
is less tedious and labourious and relatively faster 
compared to the conventional methods used to produce 
seasonal influenza vaccines (Harding & Heaton 2018). 
Moreover, the availability of various bacterial expression 
systems has made the vaccine production even more easier, 
quicker and less complicated (Legastelois et al. 2017, 
Mahalik et al. 2014). In this study, an expression plasmid 
anchoring the NS1 gene of AIV H5N1 was generated by 
recombinant DNA techniques and subsequently transfected 
into Escherichia coli (E coli) BL21 strain (DE3). The 
recombinant E. coli can be employed to produce a NS1-
based universal influenza vaccine in the future. 
MATERIALS AND METHODS
BACTERIAL STRAIN, PLASMID AND 
CHEMICALS
T h e  v i r a l  R N A  o f  A I V  H 5 N 1  A / C h i c k e n /
Malaysia/5858/2004 (H5N1) was provided by Associate 
Professor Dr. Sharifah Syed Hassan from the Monash 
University Sunway. Bacterial hosts used in this study 
were E. coli strain Top10 for plasmid maintenance and 
E. coli BL21 strain (DE3) (Invitrogen, United States) for 
protein expression. Plasmid vectors used in this study 
were pGEM-T Easy (Promega, United States) for TA-
cloning and pRSET B (Invitrogen, United States) for 
protein expression. 
AMPLIFICATION OF NS1 GENE
The viral RNA was converted to first-strand cDNA with 
oligo-dT primers (Promega, Madison, USA) and AMV 
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reverse transcriptase (Promega, Madison, USA). The NS1 
gene of AIV A/Chicken/Malaysia/5858/2004 (H5N1) was 
amplified from the first-strand cDNA using the Accura 
High-Fidelity DNA polymerase (Lucigen Corporation, 
USA). The PCR reaction contained: Accura High-Fidelity 
DNA polymerase (1U), Accura HF reaction buffer (1X), 
dNTPs (200 µM), forward and reverse primer (1 µM), 
DNA template (55.5 ng) and nuclease-free water. The 
f o l l o w i n g  p r i m e r s  w e r e  e m p l o y e d ,  N S 1 - F : 
5’-AGCTCGAGAGATTCCAACACTGTGTCA-3 and 
NS1-R: 5’- GAATTCAACTTCTGACTCAATTGTGCT- 3’. 
The underlined sequences are XhoI and EcoRI digestion 
sites, respectively. The thermal cycling conditions were 
as follows: 94°C for 30 s, followed by 30 cycles of 
denaturation at 94°C for 15 s, annealing at 60°C for 15 s 
and extension at 72°C for 60 s, and a final extension step 
at 72°C for 10 min. The PCR product (Figure 1) was mixed 
with the 6X Purple Gel DNA loading dye (NEB, United 
Kingdom), analyzed on a 1% (w/v) agarose gel at 80 V 
for 1 h and visualized under an UV transilluminator. The 
resulting PCR product was then purified using the 
Wizard® SV Gel and PCR Clean-Up system (Promega, 
United States) prior to TA-cloning in pGEM-T Easy 
plasmid. Before ligation, A-tailing of PCR product was 
performed to add an adenine residue to the 3’-end using 
the GoTaq Flexi DNA polymerase. The reaction mixture 
contained GoTaq Flexi DNA Polymerase (2.5 U), GoTaq 
Flexi Colorless Buffer (1X), dATP (200 µM), magnesium 
chloride (4 mM), the purified NS1 gene as a template and 
nuclease-free water.
CLONING OF NS1 GENE INTO PGEM-T        
EASY TA VECTOR
Cloning of the purified NS1 gene into pGEM-T Easy TA 
vector was carried out using T4 DNA ligase (NEB, United 
Kingdom) at 1:3 (vector:insert) ratio. The ligation reaction 
was incubated overnight at 4°C and transformed into 
competent E. coli strain Top10 at 42°C for 90 s. The 
bacterial cells were then revived in 200 μl of LB broth at 
37°C and 150 rpm for 1.5 h. The culture was spread on LB 
agar containing IPTG (0.1 mM), X-gal (40 μg/mL ) and 
ampicillin (100 μg/mL) for 18 h. 
BLUE-WHITE AND COLONY                              
PCR SCREENING
Positive colonies carrying the pGEM-T-NS1 plasmid were 
identified by blue-white screening in the presence of X-gal 
and IPTG. Bacterial colonies containing the PGEM-T-NS1 
plamid appeared as white colonies while blue colonies 
indicated negative colonies. The white colonies were 
further validated using the colony PCR screening. In this 
study, five white colonies were picked and mixed with 
Phosphate Buffer Saline (PBS: 4.3 mM Na2HPO4, 137 mM 
NaCl, 2.7 mM KCL, 1.4 mM KH2PO4, pH 7.6). The cell 
suspension was then added to the EconoTaq Plus 2x 
Mastermix containing the NS1 primer pair for PCR 
screening. The PCR product was analyzed on a 1% (w/v) 
agarose gel as described in 2.2.
DIGESTION OF PGEM-T- NS1 AND PRSET B 
PLASMID
The pGEM-T-NS1 was isolated using the HiYield Plasmid 
Mini Kit 2.0 (Yeastern Biotech, Taiwan). The purity and 
yield of the plasmid was measured at A260 and A280 using 
a Nanodrop 2000C spectrophotometer (Thermo Fisher 
Scientific, United States). The NS1 gene was liberated from 
pGEM-T-NS1 using EcoRI and XhoI at 37°C for 4 h. The 
E. coli expression plasmid pRSET B was linearized with 
the same enzymes. The digested NS1 and pRSET B were 
mixed with 6X Purple Gel DNA loading dye and analyzed 
using agarose gel electrophoresis as described earlier. The 
digested products were then excised and purified from the 
agarose gel using the Wizard® SV Gel and PCR Clean-Up 
system (Promega, USA). 
CLONING OF NS1 GENE INTO PRSET B 
PLASMID
Ligation of the purified NS1 gene with the linearized pRSET 
B plasmid was carried out overnight at 16°C using T4 DNA 
ligase. The ligation product was first transfected into 
competent E. coli strain Top10 cells using heat shock at 
42°C for 90 s. Selection of postitive colonies was carried 
out using blue-white and colony PCR screening. The 
FIGURE 1. The schematic diagram of the amplified NS1 gene (687 bp). The amplicon harbours XhoI and EcoRI cutting sites at its 
5’- and 3’-ends, respectively 
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recombinant pRSET B-NS1 plasmid was then isolated and 
transfected into competent E. coli BL21 strain (DE3) cells 
using heat shock at 42°C for 45 s. The bacterial cells were 
revived with 200 μl of LB broth at 37°C, 150 rpm. The 
bacterial suspension was spread on LB agar containing 100 
μg/ml ampicillin. The bacterial colonies carrying the 
pRSET B-NS1 plasmid were screened using PCR. 
SEQUENCING OF PRSET B-NS1
pRSET B-NS1 was isolated and purified as previously 
described in section 2.4. The plasmid was then sequenced 
to determine the NS1 gene sequence in the plasmid. The 
nucleotide sequences of the NS1 gene was compared with 
that of AIV A/Chicken/Malaysia/5858/2004 (H5N1) using 
the Basic Local Alignment Search Tool (BLAST). 
RESULTS AND DISCUSSION
AMPLIFICATION OF NS1 GENE
The NS1 gene (687 bp) of influenza A strain H5N1 (A/
chicken/Malaysia/5858/2004) was successfully amplified 
as observed in Figure 2. Although the amount of template 
used in the PCR reaction was relatively low (55.5 ng), due 
to the high performance of Accura High-Fidelity DNA 
polymerase, the amount of amplicon was sufficiently 
produced for the A-tailing and TA cloning experiments 
(Ishino & Ishino 2014). The Accura High-Fidelity Pfu DNA 
polymerase possesses higher ability to prevent the 
occurrence of gene mutations in the amplification 
processess than Taq DNA polymerases (McInerney, Adams 
& Hadi 2014). However, Pfu DNA polymerase produces 
blunt-end PCR products, therefore, additional adenosine 
residues are added to the 3’-end of PCR products using Taq 
DNA polymerase (Yu et al. 2014) in order to facilitate the 
subsequent TA cloning process in pGEM-T Easy. The PCR 
product was later purified to remove unwanted traces of 
enzyme, primers and salts that will interfere with the 
subsequent DNA ligation (Carson et al. 2019).
CLONING OF NS1 GENE INTO PGEM-T EASY TA 
VECTOR
The 687-bp amplicon was cloned into a pGEM-T Easy 
vector in order to improve restriction digestion efficiency 
(Sambrook & Russel 2001). The pGEM-T Easy vector is a 
TA-cloning vector which employs complementarity 
between 3’-T overhang in the vector and 3’-A overhang in 
the PCR fragment (Aranishi & Okimoto 2004). 
Transformation of pGEM-T-NS1 into E. coli strain Top 10 
cells was made possible by using divalent or multivalent 
cations such as calcium and magnesium that enable foreign 
DNA molecules to cross the bacterial membrane (Tan et 
al. 2017). The ampicillin-resistant gene in the pGEM-T 
vector confered the antibiotic resistance to the positive 
transformants. This allows selection of postive colonies on 
LB agar supplemented with ampicillin (Tan, Syed Hassan 
& Yap 2017). Besides, the insertion of NS1 gene into the 
pGEM-T Easy vector inactivates β–galactosidase enzyme 
that is responsible to oxidize lactose medium into a blue 
product under the influence of lac/tac promoter (Sambrook 
& Russel 2001). The activation of lac/tac promoter is 
usually induced by the addition of IPTG (Yao, Hart & An 
2016). Therefore bacterial colonies carrying the pGEM-T-
FIGURE 2. The PCR product of AIV H5N1 NS1 gene. Lanes L: 1 kb DNA ladder; 1: amplified NS1 gene. A bright band below 750 
bp was observed and it correlated well with the molecular size of the NS1 gene
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NS1 appeared as white colonies whereas the negative 
transformants turned out as blue colonies (results not 
shown). In order to better validate the presence of pGEM-
T-NS1 in those white colonies, the colony PCR (Tan, Syed 
Hassan & Yap 2017) was performed and the amplicon was 
then visualized using agarose gel electrophoresis. Among 
the five selected colonies, four of them showed a band 
below the 750-bp marker (Figure 3). This is in parallel to 
the expected size of the NS1 gene (687 bp).
DIGESTION OF PGEM-T-NS1 AND PRSET B 
PLASMID
The primer pair used to amplify the NS1 gene was designed 
to harbour EcoRI and  XhoI restriction sites at the 3’-end 
and 5’-end of the PCR product, respectively. The pGEM-
T-NS1 gene and pRSET B plasmid were digested by those 
two restriction enzymes prior to ligation. This generated 
compatible cloning sites on the NS1 gene and pRSET B 
vector. The RE digestion was carried out for 4 h in this 
study in order to ensure high digestion efficiency (Ihle & 
Michaelsen 2000). Figure 4 shows the restriction products, 
P (pGEM-T Easy and NS1) and Pb (linearized pRSET B). 
Upon incubation, the RE were heat inactivated at 65ºC for 
10 min to avoid unspecific cutting (Fischer, Mgboji & Liu 
2018). Before proceeding to ligation, the digested  products 
were purified from unwanted materials that may interfere 
with the ligation (Lessard 2013).
CLONING OF NS1 GENE INTO PRSET B 
PLASMID
pRSET B-NS1 (Figure 5) was multiplied in E. coli Top10 
in order to produce sufficient amount of plasmid for 
transformation into E. coli BL21 (DE3) (Casali & Preston 
2003). pRSET vectors are designed to ensure high-level 
protein expression of cloned genes in E. coli carrying the 
lambda (λ) phage DE3 gene that tightly regulates the 
activities of RNA polymerase (Horiuchi 2018; Rosano & 
Ceccarelli  2014). In addition, pRSET vectors contain a 
polyhistidine tag that is useful for metal binding in affinity 
chromatography protein purification (Terpe 2006) and an 
enterokinase cleavage recognition sequence to allow 
subsequent removal of N-terminal fusion peptides from 
the purified recombinant proteins in order to prevent 
structural and functional disruption (Ramos et al. 2004).
SEQUENCING OF NS1 GENE IN PRSET B-NS1
The DNA sequencing analysis showed that the NS1 gene 
was located downstream of the N-terminal fusion peptides 
and in frame with the cloning sites in the vector (Figure 
5). The nucelotide sequence was also aligned with that of 
influenza A/Chicken/Malaysia/5858/2004 (H5N1). The 
BLAST findings indicated that the amplified NS1 gene was 
97% similar to that of the A/Chicken/Malaysia/5858/2004 
(H5N1). Some point mutations were introduced in the NS1 
gene and this is mainly due to the low fidelity of the viral 
RNA polymerase that renders a high mutational rate to the 
viral genome meanwhile lacks of proofreading ability when 
the viral genome is replicated in host cells (Kautz & 
Forrester 2018). When the NS1 gene sequence was 
translated to amino acid sequence, the similarity was 
retained as high as 96%. There were nine amino acid 
changes in the NS1 sequence: G47S, K75E, A81T, K95R, 
A106V, V122N, T190S, F196Y and P210L (Figure 6). 
However, this alteration did not affect the antigenic sites 
of NS1 protein: NTVSSFQV at position 4-11 (Ishizuka et 
FIGURE 3. Colony PCR screening of 5 white colonies formed on the LB agar plate. Lanes 1-5: white colonies; L: 1-kb DNA ladder. 
The arrow indicates the amplified NS1 gene
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FIGURE 4. Restriction digestion using EcoRI and XhoI enzymes. In (a), two distinct fragments, around 3000 bp and 687 bp, were 
observed on the gel after pGEM-T-NS1 (P) was digested with the RE. In (b), the linearized pRSET B (Pb) was about 3000 bp in 
size. Lane L: 1kb DNA Ladder
FIGURE 5. pRSET B-NS1 expression vector. The NS1 gene is located downstream of the N-terminal fusion peptides
FIGURE 6. The mutated amino acid in the recombinant NS1 protein. [Ref (NS)] denotes the NS1 protein of AIV H5N1 A/Chicken/
Malaysia/5858/2004 (H5N1); [Rec (NS1)] is the NS1 protein expressed from pRSET B-NS1. The bold sequences are antigenic 
sites and mutated amino acids are bold and boxed. The mutations are not located in the antigenic sites
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al. 2009), FQVDCFLWHV at position 9-18 (Alexander et 
al. 2010), DRLRRDQKS at position 34-42 (Jameson et al. 
1999), ETATRAGKQI at position 55-64 (Sequence Feature 
Details (Influenza A_NS1_experimentally-determined-
epitope_55(10), accessed on 29.02.2020), FSVIFDRL at 
p o s i t i o n  1 2 9 - 1 3 6  ( Z h o n g  e t  a l .  2 0 0 3 ) , 
VKNAIGVLIGGLEWNDN within residues 169-185 
(Richards et al. 2018), RAFTEEGAIVGEISPLPS at position 
143-160 (Richards et al. 2011) and WNDNT at position 
182-186 (Wen et al. 2015). It is therefore believed that the 
NS1 protein expressed from the amplified NS1 gene will 
retain its antigenicity. However this needs to be autheticated 
using immunoassays such as Western blotting and ELISA 
using anti-NS1 antibody or antisera.
CONCLUSION
The NS1 gene of influenza A/Chicken/Malaysia/5858/2004 
(H5N1) virus was successfully amplified and cloned into 
a pRSET B expression vector. The recombinant plasmid, 
pRSET B-NS1 was successfully transformed into E. coli 
BL21 strain (DE3). The DNA sequencing analysis showed 
that the NS1 gene sequence was 97% similar to that of the 
parental H5N1 virus. This recombinant NS1 can be further 
tested with immunoassays for its antigenicity and 
immunogenicity, and potential as a universal influenza 
vaccine candidate.
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